baumannii Multidrug-Resistant Acinetobacter Ventilator-Associated Pneumonia by Inflammation in a Mouse Model of Azithromycin Attenuates Lung
暂无分享,去创建一个
Shigeru | K. Yanagihara | Y. Morinaga | H. Hasegawa | Kakeya | Shigeki Nakamura | H. Mikamo | Y. Harada | Koichi Yamada | Y. Migiyama | K. Nagaoka | Kohno | Imamura | Yoshifumi
[1] M. McConnell,et al. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. , 2013, FEMS microbiology reviews.
[2] Eric P. Skaar,et al. Host–microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection , 2012, Cellular microbiology.
[3] J. Rello,et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia , 2010, European Respiratory Journal.
[4] S. Brody,et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis , 2010, Respiratory research.
[5] K. Kaye,et al. Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System , 2010, Antimicrobial Agents and Chemotherapy.
[6] V. Tam,et al. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. , 2010, The Journal of infectious diseases.
[7] M. Kempf,et al. The virulence variability of different Acinetobacter baumannii strains in experimental pneumonia. , 2010, The Journal of infection.
[8] C. Roussos,et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Lisa L Maragakis,et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Yehuda Carmeli,et al. Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli , 2007, Antimicrobial Agents and Chemotherapy.
[11] C. Price,et al. Epidemiologic, Clinical, and Economic Evaluation of an Outbreak of Clonal Multidrug-Resistant Acinetobacter baumannii Infection in a Surgical Intensive Care Unit , 2007, Infection Control & Hospital Epidemiology.
[12] J. Quinn,et al. Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004 , 2007, Journal of Clinical Microbiology.
[13] M. Hentzer,et al. Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice , 2007, Antimicrobial Agents and Chemotherapy.
[14] J. Ramirez,et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. , 2007, American journal of respiratory and critical care medicine.
[15] M. Kaufmann,et al. Identification of Acinetobacter baumannii by Detection of the blaOXA-51-like Carbapenemase Gene Intrinsic to This Species , 2006, Journal of Clinical Microbiology.
[16] D. Wareham,et al. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases , 2006, Annals of Clinical Microbiology and Antimicrobials.
[17] F. Can,et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. , 2006, International journal of antimicrobial agents.
[18] P. Fournier,et al. The epidemiology and control of Acinetobacter baumannii in health care facilities. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] K. Asano,et al. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. , 2003, Mediators of inflammation.
[20] F. Fernández-Cuenca,et al. In vitro Activity of Azithromycin in Combination with Amikacin, Ceftazidime, Ciprofloxacin or Imipenem against Clinical Isolates of Acinetobacter baumannii , 2003, Chemotherapy.
[21] C. Cabellos,et al. Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii , 2002, Antimicrobial Agents and Chemotherapy.
[22] Y. Hirakata,et al. Effects of Parenterally Administered Ciprofloxacin in a Murine Model of Pulmonary Pseudomonas aeruginosa Infection Mimicking Ventilator-Associated Pneumonia , 2001, Chemotherapy.
[23] M. Sole,et al. Analysis of factors related to the development of ventilator-associated pneumonia: use of existing databases. , 2000, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[24] F. J. Caballero,et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. , 2000, The Journal of antimicrobial chemotherapy.
[25] M. Wolff,et al. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem , 1997, Antimicrobial agents and chemotherapy.
[26] J. Golden,et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects , 1996, Antimicrobial agents and chemotherapy.
[27] S. Kamihira,et al. Clinical characteristics of tertiary hospital patients from whom Acinetobacter calcoaceticus-Acinetobacter baumannii complex strains were isolated. , 2012, Internal medicine.
[28] R. Weinstein,et al. Acinetobacter infection. , 2008, The New England journal of medicine.
[29] K. Yanagihara,et al. Lipopolysaccharide Induces Mucus Cell Metaplasia in Mouse Lung. , 2001, American journal of respiratory cell and molecular biology.